NattoPharma has entered a new Supply and Licence agreement with the Lebanon based company Omicron Pharmaceuticals. Omicron Pharmaceuticals will add MenaQ7 to products complimenting their portfolio directed toward patients suffering from cardiovascular and bone related diseases. "I see MenaQ7 as a breakthrough in cardiovascular and osteoporosis management. With the help of MenaQ7, both atherosclerosis and osteoporosis can be prevented/treated together. MenaQ7 is a unique product that can help patients suffering from hip fractures which is very common in our region. We look forward to introducing MenaQ7 to the Middle East market and we are confident that this product will bring us closer to achieve our commitment to our customers to help them lead a healthier life," says Dr. Hisham Ramadan, Market Manager at Omicron Pharmaceuticals.

Likewise NattoPharma's VP of Sales and Maketing, Siri Stabel Olsen is very optimistic and is looking forward to extending the MenaQ7 products to a new area. Omicron Pharmaceuticals will introduce MenaQ7 to Lebanon, Saudi Arabia, Jordan and Syria.  

 

 For further information, please contact:

 

Siri Stabel Olsen

VP Sales & Marketing

Phone +47 992 52 274

 

Morten Sundstø

IR and Communication

Phone + 47 950 61 860